Information de reference pour ce titreAccession Number: | 00008626-200502280-00010.
|
Author: | Fittipaldi, Antonio; Giacca, Mauro *
|
Institution: | Molecular Medicine Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99, 34012 Trieste, Italy Laboratorio di Biologia Molecolare, Scuola Normale Superiore, Pisa, Italy
|
Title: | |
Source: | Advanced Drug Delivery Reviews. 57(4):597-608, February 2005.
|
Abstract: | : The Tat protein of HIV-1 is a powerful transactivator of gene expression. By interacting with a structured RNA sequence at the 5' end of the viral mRNA, it promotes the remodeling of chromatin and the recruitment of processive RNA polymerase complexes at the viral promoter. In addition to these transcriptional functions, a short amino acid motif, highly enriched in basic amino acids, promotes the export of the protein from the expressing cells. Once in the extracellular environment, the same basic domain of Tat binds to cell surface heparan sulfate proteoglycans; through this interaction, the protein is internalized by a variety of different cell types. Cellular internalization of Tat and Tat fusion proteins requires the integrity of cell membrane lipid rafts and mainly occurs through caveolar endocytosis. The Tat basic domain, when attached to large protein cargos, also mediates their efficient cellular internalization and can be thus utilized for transcellular protein transduction. This property has already been successfully exploited for the delivery of heterologous proteins, nanoparticles, liposomes, phage and viral vectors, and plasmid DNA. The biological significance of intercellular Tat trafficking in the context of viral infection still remains elusive.
(C) 2005Elsevier, Inc.
|
Author Keywords: | Encocytosis; Human immunodeficiency virus type 1 (HIV-1); Lipid rafts; Protein transduction; Transactivation.
|
References: | [1]. K.T. Jeang, H. Xiao, E.A. Rich. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J. Biol. Chem. 274 (1999) 28837-28840.
[2]. W.C. Greene, B.M. Peterlin. Charting HIV's remarkable voyage through the cell: basic science as a passport to future therapy. Nat. Med. 8 (2002) 673-680.
[3]. A. Marcello, M. Zoppe', M. Giacca. Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator. IUBMB Life. 51 (2001) 175-181.
[4]. M. Lusic, A. Marcello, A. Cereseto, M. Giacca. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J. 22 (2003) 6550-6561.
[5]. E. Verdin, P. Jr Paras, C. Van Lint. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J. 12 (1993) 3249-3259.
[6]. P. Wei, M.E. Garber, S.-M. Fang, W.H. Fisher, K.A. Jones. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 92 (1998) 451-462.
[7]. F. Kashanchi, G. Piras, M.F. Radonovich, J.F. Duvall, A. Fattaey, C.M. Chiang, R.G. Roeder, J.N. Brady. Direct interaction of human TFIID with the HIV-1 transactivator Tat. Nature. 367 (1994) 295-299.
[8]. P. Veschambre, A. Roisin, P. Jalinot. Biochemical and functional interaction of the human immunodeficiency virus type 1 Tat transactivator with the general transcription factor TFIIB. J. Gen. Virol. 78 (1997) 2235-2245.
[9]. P. Veschambre, P. Simard, P. Jalinot. Evidence for functional interaction between the HIV-1 Tat transactivator and the TATA box binding protein in vivo. J. Mol. Biol. 250 (1995) 169-180.
[10]. C.A. Parada, R.G. Roeder. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature. 384 (1996) 375-378.
[11]. J.D. Weissman, J.A. Brown, T.K. Howcroft, J. Hwang, A. Chawla, P.A. Roche, L. Schiltz, Y. Nakatani, D.S. Singer. HIV-1Tat binds TAFII250 and represses TAFII250-dependent transcription of major histocompatibility class I genes. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 11601-11606.
[12]. F. Wu-Baer, D. Sigman, R.B. Gaynor. Specific binding of RNA polymerase II to the human immunodeficiency virus trans-activating region RNA is regulated by cellular cofactors and Tat. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7153-7157.
[13]. K.T. Jeang, R. Chun, N.H. Lin, A. Gatignol, C.G. Glabe, H. Fan. In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J. Virol. 67 (1993) 6224-6233.
[14]. G. Marzio, M. Tyagi, M.I. Gutierrez, M. Giacca. HIV-1 Tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13519-13524.
[15]. M. Benkirane, R.F. Chun, H. Xiao, V.V. Ogryzko, B.H. Howard, Y. Nakatani, K.T. Jeang. Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat. J. Biol. Chem. 273 (1998) 24898-24905.
[16]. E. Col, C. Caron, D. Seigneurin-Berny, J. Gracia, A. Favier, S. Khochbin. The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat. J. Biol. Chem. 276 (2001) 28179-28184.
[17]. J. Kamine, B. Elangovan, T. Subramanian, D. Coleman, G. Chinnadurai. Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. Virology. 216 (1996) 357-366.
[18]. A. Marcello, M. Lusic, G. Pegoraro, V. Pellegrini, F. Beltram, M. Giacca. Nuclear organization and the control of HIV-1 transcription. Gene. 326 (2004) 1-11.
[19]. P. Bayer, M. Kraft, A. Ejchart, M. Westendorp, R. Frank, P. Rosch. Structural studies of HIV-1 Tat protein. J. Mol. Biol. 247 (1995) 529-535.
[20]. A.D. Frankel, C.O. Pabo. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 55 (1988) 1189-1193.
[21]. M. Green, P.M. Loewenstein. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell. 55 (1988) 1179-1188.
[22]. E. Vives, P. Brodin, B. Lebleu. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997) 16010-16017.
[23]. I.A. Ignatovich, E.B. Dizhe, A.V. Pavlotskaya, B.N. Akifiev, S.V. Burov, S.V. Orlov, A.P. Perevozchikov. Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. J. Biol. Chem. 278 (2003) 42625-42636.
[24]. T. Suzuki, S. Futaki, M. Niwa, S. Tanaka, K. Ueda, Y. Sugiura. Possible existence of common internalization mechanisms among arginine-rich peptides. J. Biol. Chem. 277 (2002) 2437-2443.
[25]. P.A. Wender, D.J. Mitchell, K. Pattabiraman, E.T. Pelkey, L. Steinman, J.B. Rothbard. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 13003-13008.
[26]. A. Prochiantz. Homeodomain-derived peptides. In and out of the cells. Ann. N.Y. Acad. Sci. 886 (1999) 172-179.
[27]. E. Vives, J.P. Richard, C. Rispal, B. Lebleu. TAT peptide internalization: seeking the mechanism of entry. Curr. Protein Pept. Sci. 4 (2003) 125-132.
[28]. M. Silhol, M. Tyagi, M. Giacca, B. Lebleu, E. Vives. Different mechanisms for cellular internalization of the HIV-1 Tat derived cell penetrating peptide and recombinant proteins fused to Tat. Eur. J. Biochem. 269 (2002) 494-501.
[29]. J.P. Richard, K. Melikov, E. Vives, C. Ramos, B. Verbeure, M.J. Gait, L.V. Chernomordik, B. Lebleu. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278 (2003) 585-590.
[30]. D.A. Mann, A.D. Frankel. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J. 10 (1991) 1733-1739.
[31]. M. Rusnati, G. Tulipano, C. Urbinati, E. Tanghetti, R. Giuliani, M. Giacca, M. Ciomei, A. Corallini, M. Presta. The basic domain in HIV-1 Tat protein as a target for polysulfated heparin-mimicking extra-cellular Tat antagonists. J. Biol. Chem. 273 (1998) 16027-16037.
[32]. M. Rusnati, G. Tulipano, D. Spillmann, E. Tanghetti, P. Oreste, G. Zoppetti, M. Giacca, M. Presta. Multiple interactions of HIV-1 Tat protein with size-defined heparin oligosaccharides. J. Biol. Chem. 274 (1999) 28198-28205.
[33]. M. Rusnati, D. Coltrini, P. Oreste, G. Zoppetti, A. Albini, D. Noonan, F. d'Adda di Fagagna, M. Giacca, M. Presta. Interaction of HIV-1 Tat protein with heparin. J. Biol. Chem. 272 (1997) 11313-11320.
[34]. A. Ziegler, J. Seelig. Interaction of the protein transduction domain of HIV-1 TAT with heparan sulfate: binding mechanism and thermodynamic parameters. Biophys. J. 86 (2004) 254-263.
[35]. S. Hakansson, M. Caffrey. Structural and dynamic properties of the HIV-1 tat transduction domain in the free and heparin-bound states. Biochemistry. 42 (2003) 8999-9006.
[36]. K. Watson, N.J. Gooderham, D.S. Davies, R.J. Edwards. Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides. Biochem. Pharmacol. 57 (1999) 775-783.
[37]. S. Hakansson, A. Jacobs, M. Caffrey. Heparin binding by the HIV-1 tat protein transduction domain. Protein Sci. 10 (2001) 2138-2139.
[38]. E. Ruoslahti. Proteoglycans in cell regulation. J. Biol. Chem. 264 (1989) 13369-13372.
[39]. M. Yanagishita, V.C. Hascall. Cell surface heparan sulfate proteoglycans. J. Biol. Chem. 267 (1992) 9451-9454.
[40]. J.D. Esko. Genetic analysis of proteoglycan structure, function and metabolism. Curr. Opin. Cell Biol. 3 (1991) 805-816.
[41]. M. Tyagi, M. Rusnati, M. Presta, M. Giacca. Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276 (2001) 3254-3261.
[42]. M. Maccarana, B. Casu, U. Lindahl. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem. 268 (1993) 23898-23905.
[43]. D. Spillmann, D. Witt, U. Lindahl. Defining the interleukin-8-binding domain of heparan sulfate. J. Biol. Chem. 273 (1998) 15487-15493.
[44]. M. Lyon, J.T. Gallagher. Hepatocyte growth factor/scatter factor: a heparan sulphate-binding pleiotropic growth factor. Biochem. Soc. Trans. 22 (1994) 365-370.
[45]. D.A. Lappi, W. Ying, I. Barthelemy, D. Martineau, I. Prieto, L. Benatti, M. Soria, A. Baird. Expression and activities of a recombinant basic fibroblast growth factor-saporin fusion protein. J. Biol. Chem. 269 (1994) 12552-12558.
[46]. B.A. Sosnowski, A.M. Gonzalez, L.A. Chandler, Y.J. Buechler, G.F. Pierce, A. Baird. Targeting DNA to cells with basic fibroblast growth factor (FGF2). J. Biol. Chem. 271 (1996) 33647-33653.
[47]. A. Albini, R. Soldi, D. Giunciuglio, E. Giraudo, R. Benelli, L. Primo, D. Noonan, M. Salio, G. Camussi, W. Rockl, F. Bussolino. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat. Med. 2 (1996) 1371-1375.
[48]. M. Rusnati, E. Tanghetti, P. Dell'Era, A. Gualandris, M. Presta. Alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. Mol. Biol. Cell. 8 (1997) 2449-2461.
[49]. S.L. Schmid. Clathrin-coated vesicle formation and protein sorting: an integrated process. Annu. Rev. Biochem. 66 (1997) 511-548.
[50]. R.G. Anderson. The caveolae membrane system. Annu. Rev. Biochem. 67 (1998) 199-225.
[51]. A.M. Fra, E. Williamson, K. Simons, R.G. Parton. De novo formation of caveolae in lymphocytes by expression of VIP21-caveolin. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 8655-8659.
[52]. K. Simons, D. Toomre. Lipid rafts and signal transduction. Nat. Rev., Mol. Cell Biol. 1 (2000) 31-39.
[53]. B.J. Nichols, J. Lippincott-Schwartz. Endocytosis without clathrin coats. Trends Cell Biol. 11 (2001) 406-412.
[54]. L. Pelkmans, J. Kartenbeck, A. Helenius. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat. Cell Biol. 3 (2001) 473-483.
[55]. A. Fittipaldi, A. Ferrari, M. Zoppe, C. Arcangeli, V. Pellegrini, F. Beltram, M. Giacca. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem. 278 (2003) 34141-34149.
[56]. A. Ferrari, V. Pellegrini, C. Arcangeli, A. Fittipaldi, M. Giacca, F. Beltram. Caveolae-mediated internalization of extracellular HIV-1 Tat fusion proteins visualized in real time. Molec. Ther. 8 (2003) 284-294.
[57]. M. Stahlhut, B. van Deurs. Identification of filamin as a novel ligand for caveolin-1: evidence for the organization of caveolin-1-associated membrane domains by the actin cytoskeleton. Mol. Biol. Cell. 11 (2000) 325-337.
[58]. P. Thomsen, K. Roepstorff, M. Stahlhut, B. van Deurs. Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol. Biol. Cell. 13 (2002) 238-350.
[59]. A. Benmerah, M. Bayrou, N. Cerf-Bensussan, A. Dautry-Varsat. Inhibition of clathrin-coated pit assembly by an Eps15 mutant. J. Cell. Sci. 112(Pt 9) (1999) 1303-1311.
[60]. G. David. Integral membrane heparan sulfate proteoglycans. FASEB J. 7 (1993) 1023-1030.
[61]. B.J. Nichols, A.K. Kenworthy, R.S. Polishchuk, R. Lodge, T.H. Roberts, K. Hirschberg, R.D. Phair, J. Lippincott-Schwartz. Rapid cycling of lipid raft markers between the cell surface and Golgi complex. J. Cell Biol. 153 (2001) 529-541.
[62]. M. Muniz, H. Riezman. Intracellular transport of GPI-anchored proteins. EMBO J. 19 (2000) 10-15.
[63]. L.A. Fransson, G. Edgren, B. Havsmark, A. Schmidtchen. Recycling of a glycosylphosphatidylinositol-anchored heparan sulphate proteoglycan (glypican) in skin fibroblasts. Glycobiology. 5 (1995) 407-415.
[64]. F. Cheng, K. Mani, J. van den Born, K. Ding, M. Belting, L.A. Fransson. Nitric oxide-dependent processing of heparan sulfate in recycling S-nitrosylated glypican-1 takes place in caveolin-1-containing endosomes. J. Biol. Chem. 277 (2002) 44431-44439.
[65]. I.V. Majoul, P.I. Bastiaens, H.D. Soling. Transport of an external Lys-Asp-Glu-Leu (KDEL) protein from the plasma membrane to the endoplasmic reticulum: studies with cholera toxin in Vero cells. J. Cell Biol. 133 (1996) 777-789.
[66]. A. Schmitz, H. Herrgen, A. Winkeler, V. Herzog. Cholera toxin is exported from microsomes by the Sec61p complex. J. Cell Biol. 148 (2000) 1203-1212.
[67]. P.A. Orlandi, P.K. Curran, P.H. Fishman. Brefeldin A blocks the response of cultured cells to cholera toxin. Implications for intracellular trafficking in toxin action. J. Biol. Chem. 268 (1993) 12010-12016.
[68]. R. Fischer, K. Kohler, M. Fotin-Mleczek, R. Brock. A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J. Biol. Chem. 279(13) (2004) 12625-12635.
[69]. A. Sacchetti, V. Cappetti, P. Marra, R. Dell'Arciprete, T. El Sewedy, C. Crescenzi, S. Alberti. Green fluorescent protein variants fold differentially in prokaryotic and eukaryotic cells. J. Cell. Biochem., Suppl. 2001;117-128.
[70]. N. Bonifaci, R. Sitia, A. Rubartelli. Nuclear translocation of an exogenous fusion protein containing HIV Tat requires unfolding. AIDS. 9 (1995) 995-1000.
[71]. J.S. Wadia, R.V. Stan, S.F. Dowdy. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10(3) (2004) 310-315.
[72]. P.S. Kabouridis, M. Hasan, J. Newson, D.W. Gilroy, T. Lawrence. Inhibition of NF-kappa B activity by a membrane-transducing mutant of I kappaB-alpha. J. Immunol. 169 (2002) 2587-2593.
[73]. H.Y. Wang, T. Fu, G. Wang, G. Zeng, D.M. Perry-Lalley, J.C. Yang, N.P. Restifo, P. Hwu, R.F. Wang. Induction of CD4(+) T cell-dependent antitumor immunity by Tat-mediated tumor antigen delivery into dendritic cells. J. Clin. Invest. 109 (2002) 1463-1470.
[74]. N. Shibagaki, M.C. Udey. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J. Immunol. 168 (2002) 2393-23401.
[75]. K. Datta, C. Sundberg, S.A. Karumanchi, D. Mukhopadhyay. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res. 61 (2001) 1768-1775.
[76]. J. Krosl, P. Austin, N. Beslu, E. Kroon, R.K. Humphries, G. Sauvageau. In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein. Nat. Med. 9 (2003) 1428-1432.
[77]. M. Lewin, N. Carlesso, C.H. Tung, X.W. Tang, D. Cory, D.T. Scadden, R. Weissleder. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18 (2000) 410-414.
[78]. A. Eguchi, T. Akuta, H. Okuyama, T. Senda, H. Yokoi, H. Inokuchi, S. Fujita, T. Hayakawa, K. Takeda, M. Hasegawa, M. Nakanishi. Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells. J. Biol. Chem. 276 (2001) 26204-26210.
[79]. J.P. Gratton, J. Yu, J.W. Griffith, R.W. Babbitt, R.S. Scotland, R. Hickey, F.J. Giordano, W.C. Sessa. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat. Med. 9 (2003) 357-363.
[80]. V.P. Torchilin, R. Rammohan, V. Weissig, T.S. Levchenko. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8786-8791.
[81]. S. Sandgren, F. Cheng, M. Belting. Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. Role for cell-surface proteoglycans. J. Biol. Chem. 277 (2002) 38877-38883.
[82]. S.R. Schwarze, A. Ho, A. Vocero-Akbani, S.F. Dowdy. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 285 (1999) 1569-1572.
[83]. S. Asoh, I. Ohsawa, T. Mori, K. Katsura, T. Hiraide, Y. Katayama, M. Kimura, D. Ozaki, K. Yamagata, S. Ohta. Protection against ischemic brain injury by protein therapeutics. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 17107-17112.
[84]. G. Cao, W. Pei, H. Ge, Q. Liang, Y. Luo, F.R. Sharp, A. Lu, R. Ran, S.H. Graham, J. Chen. In vivo delivery of a Bcl-xL fusion protein containing the Tat protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 22 (2002) 5423-5431.
[85]. A.B. Gustafsson, M.R. Sayen, S.D. Williams, M.T. Crow, R.A. Gottlieb. Tat protein transduction into isolated perfused hearts: Tat-apoptosis repressor with caspase recruitment domain is cardioprotective. Circulation. 106 (2002) 735-739.
[86]. K. Inagaki, L. Chen, F. Ikeno, F.H. Lee, K. Imahashi, D.M. Bouley, M. Rezaee, P.G. Yock, E. Murphy, D. Mochly-Rosen. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation. 108 (2003) 2304-2307.
[87]. H.C. Chang, F. Samaniego, B.C. Nair, L. Buonaguro, B. Ensoli. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS. 11 (1997) 1421-1431.
[88]. H. Xia, Q. Mao, B.L. Davidson. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat. Biotechnol. 19 (2001) 640-644.
[89]. C.S. Crumpacker. Ganciclovir. N. Engl. J. Med. 335 (1996) 721-729.
[90]. E. Tasciotti, M. Zoppe, M. Giacca. Transcellular transfer of active HSV-1 thymidine kinase mediated by an 11-amino-acid peptide from HIV-1 Tat. Cancer Gene Ther. 10 (2003) 64-74.
[91]. M. Lotz, I. Clark-Lewis, V. Ganu. HIV-1 transactivator protein Tat induces proliferation and TGF beta expression in human articular chondrocytes. J. Cell Biol. 124 (1994) 365-371.
[92]. G. Zauli, B.R. Davis, M.C. Re, G. Visani, G. Furlini, M. La Placa. Tat protein stimulates production of transforming growth factor-beta 1 by marrow macrophages: a potential mechanism for human immunodeficiency virus-1-induced hematopoietic suppression. Blood. 80 (1992) 3036-3043.
[93]. M.O. Westendorp, M. Li-Weber, R.W. Frank, P.H. Krammer. Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J. Virol. 68 (1994) 4177-4185.
[94]. G. Scala, M.R. Ruocco, C. Ambrosino, M. Mallardo, V. Giordano, F. Baldassarre, E. Dragonetti, I. Quinto, S. Venuta. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J. Exp. Med. 179 (1994) 961-971.
[95]. S.R. Opalenik, J.T. Shin, J.N. Wehby, V.K. Mahesh, J.A. Thompson. The HIV-1 TAT protein induces the expression and extracellular appearance of acidic fibroblast growth factor. J. Biol. Chem. 270 (1995) 17457-17467.
[96]. L.M. Nabell, R.H. Raja, P.P. Sayeski, A.J. Paterson, J.E. Kudlow. Human immunodeficiency virus 1 Tat stimulates transcription of the transforming growth factor alpha gene in an epidermal growth factor-dependent manner. Cell Growth Differ. 5 (1994) 87-93.
[97]. R.K. Puri, B.B. Aggarwal. Human immunodeficiency virus type 1 tat gene up-regulates interleukin 4 receptors on a human B-lymphoblastoid cell line. Cancer Res. 52 (1992) 3787-3790.
[98]. S.F. Purvis, D.L. Georges, T.M. Williams, M.M. Lederman. Suppression of interleukin-2 and interleukin-2 receptor expression in Jurkat cells stably expressing the human immunodeficiency virus Tat protein. Cell. Immunol. 144 (1992) 32-42.
[99]. E. Pocsik, M. Higuchi, B.B. Aggarwal. Down-modulation of cell surface expression of p80 form of the tumor necrosis factor receptor by human immunodeficiency virus-1 tat gene. Lymphokine Cytokine Res. 11 (1992) 317-325.
[100]. B. Ensoli, L. Buonaguro, G. Barillari, V. Fiorelli, R. Gendelman, R.A. Morgan, P. Wingfield, R.C. Gallo. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67 (1993) 277-287.
[101]. G. Zauli, D. Gibellini, D. Milani, M. Mazzoni, P. Borgatti, M. La Placa, S. Capitani. Human immunodeficiency virus type 1 Tat protein protects lymphoid, epithelial, and neuronal cell lines from death by apoptosis. Cancer Res. 53 (1993) 4481-4485.
[102]. B. Ensoli, G. Barillari, S.Z. Salahuddin, R.C. Gallo, F. Wong-Staal. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 345 (1990) 84-87.
[103]. R.M. Lafrenie, L.M. Wahl, J.S. Epstein, K.M. Yamada, S. Dhawan. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J. Immunol. 159 (1997) 4077-4083.
[104]. A. Albini, R. Benelli, M. Presta, M. Rusnati, M. Ziche, A. Rubartelli, G. Paglialunga, B.F.D. Noonan. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene. 12 (1996) 289-297.
[105]. A. Albini, G. Barillari, R. Benelli, R.C. Gallo, B. Ensoli. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 4838-4842.
[106]. A. Corallini, D. Campioni, C. Rossi, A. Albini, L. Possati, M. Rusnati, G. Gazzanelli, R. Benelli, L. Masiello, V. Sparacciari, M. Presta, F. Mannello, G. Fontanini, G. Barbanti- Brodano. Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. AIDS. 10 (1996) 701-710.
[107]. M. Subramanyam, W.G. Gutheil, W.W. Bachovchin, B.T. Huber. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. J. Immunol. 150 (1993) 2544-2553.
[108]. N. Chirmule, S. Than, S.A. Khan, S. Pahwa. Human immunodeficiency virus Tat induces functional unresponsiveness in T cells. J. Virol. 69 (1995) 492-498.
[109]. R.P. Viscidi, K. Mayur, H.M. Lederman, A.D. Frankel. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science. 246 (1989) 1606-1608.
[110]. J.M. Sabatier, E. Vives, K. Mabrouk, A. Benjouad, H. Rochat, A. Duval, B. Hue, E. Bahraoui. Evidence for neurotoxic activity of Tat from human immunodeficiency virus type 1. J. Virol. 65 (1991) 961-967.
[111]. J.P. Taylor, C. Cupp, A. Diaz, M. Chowdhury, K. Khalili, S.A. Jimenez, S. Amini. Activation of expression of genes coding for extracellular matrix proteins in Tat-producing glioblastoma cells. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 9617-9621.
[112]. V. Philippon, C. Vellutini, D. Gambarelli, G. Harkiss, G. Arbuthnott, D. Metzger, R. Roubin, P. Filippi. The basic domain of the lentiviral Tat protein is responsible for damages in mouse brain: involvement of cytokines. Virology. 205 (1994) 519-529.
[113]. B.S. Weeks, D.M. Lieberman, B. Johnson, E. Roque, M. Green, P. Loewenstein, E.H. Oldfield, H.K. Kleinman. Neurotoxicity of the human immunodeficiency virus type 1 tat transactivator to PC12 cells requires the Tat amino acid 49-58 basic domain. J. Neurosci. Res. 42 (1995) 34-40.
[114]. F.M. Hofman, M.M. Dohadwala, A.D. Wright, D.R. Hinton, S.M. Walker. Exogenous tat protein activates central nervous system-derived endothelial cells. J. Neuroimmunol. 54 (1994) 19-28.
[115]. A. Nath, K. Psooy, C. Martin, B. Knudsen, D.S. Magnuson, N. Haughey, J.D. Geiger. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J. Virol. 70 (1996) 1475-1480.
[116]. A. Albini, S. Ferrini, R. Benelli, S. Sforzini, D. Giunciuglio, M.G. Aluigi, A.E.I. Proudfoot, S. Alouani, T.N.C. Wells, G. Mariani, R.L. Rabin, J.M. Farber, D.M. Noonan. HIV-1 Tat protein mimicry of chemokines. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13153-13158.
[117]. S. Mitola, S. Sozzani, W. Luini, L. Primo, A. Borsatti, H. Weich, F. Bussolino. Tat-human immunodeficiency virus-1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor receptor-1. Blood. 90 (1997) 1365-1372.
[118]. G. Barillari, R. Gendelman, R.C. Gallo, B. Ensoli. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 7941-7945.
[119]. H. Xiao, C. Neuveut, H.L. Tiffany, M. Benkirane, E.R. Rich, P.M. Murphy, K.-T. Jeang. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 11466-11471.
[120]. F. Demarchi, M.I. Gutierrez, M. Giacca. Human Immunodeficiency Virus type 1 Tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. J. Virol. 73 (1999) 7080-7086.
[121]. L. Resnick, J.R. Berger, P. Shapshak, W.W. Tourtellotte. Early penetration of the blood-brain-barrier by HIV. Neurology. 38 (1988) 9-14.
[122]. N.Q. Liu, A.S. Lossinsky, W. Popik, X. Li, C. Gujuluva, B. Kriederman, J. Roberts, T. Pushkarsky, M. Bukrinsky, M. Witte, M. Weinand, M. Fiala. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J. Virol. 76 (2002) 6689-6700.
[123]. M. Bomsel. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 3 (1997) 42-47.
[124]. M.E. Lindgren, M.M. Hallbrink, A.M. Elmquist, U. Langel. Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem. J. 377 (2004) 69-76.
|
Language: | English.
|
Document Type: | Article.
|
Journal Subset: | Pharmacology.
|
ISSN: | 0169-409X
|
NLM Journal Code: | dor, 8710523
|
DOI Number: | https://dx.doi.org/10.1016/j.add...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|